Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• In vitro studies suggest bortezomib combined with alkylating agents has synergistic antimyeloma effects.
• Combining bortezomib, cyclophosphamide, and dexamethasone is a rational approach for enhanced antitumor activity.
• Assessing the efficacy and tolerability of this combination in relapsing multiple myeloma is crucial.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of a bortezomib, cyclophosphamide, and dexamethasone combination regimen.
• To determine the response rate, remission duration, and survival outcomes in patients with relapsing multiple myeloma.
• To assess the tolerability and side effect profile of the treatment combination.

Main Methods:

• A phase II clinical trial involving 44 patients with relapsing multiple myeloma.
• Patients received intravenous bortezomib, oral cyclophosphamide, and oral dexamethasone over two courses.
• Treatment involved specific dosing and schedules for each agent, with a one-month interval between courses.

Main Results:

• A clinical response was observed in 73% of patients (32/44), including 59% partial remission and 14% complete remission.
• Side effects were generally mild and uncommon, with notable exceptions including grade 3 thrombocytopenia (15%), infection (5%), and constipation (2%).
• Responding patients had a median remission duration of 10 months, leading to significantly longer median survival (33 months) compared to non-responders (12 months).

Conclusions:

• The bortezomib-cyclophosphamide-dexamethasone combination demonstrates significant efficacy in treating relapsing multiple myeloma.
• The regimen is well-tolerated, with a manageable side effect profile, making it a viable treatment option.
• This combination therapy offers a promising therapeutic strategy for patients with relapsed or refractory multiple myeloma.